Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet

Kidney International

Volumn 82, Issue 12, 2012, Pages 1261-1270

  Lau, Wei Ling ^a   Leaf, Elizabeth M ^b   Hu, Ming Chang ^c   Takeno, Marc M ^b   Kuro O, Makoto ^c   Moe, Orson W ^c   Giachelli, Cecilia M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b University of Washington   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

chronic kidney disease; klotho; osteopontin; vascular calcification; vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; OSTEOPONTIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CALCIFICATION; ARTICLE; CALCIUM BLOOD LEVEL; CELL CULTURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HYPERPHOSPHATEMIA; MOUSE; NONHUMAN; PHOSPHATE INTAKE; PHOSPHATURIA; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN URINE LEVEL; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 84870624437     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.322     Document Type: Article

References (61)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Pilz S, Iodice S, Zittermann A et al. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011; 58: 374-382.
3. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
4. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
5. Shoben AB, Rudser KD, de Boer IH et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619.
6. Naves-Di'az M, Alvarez-Herna'ndez D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078.
7. Becker LE, Koleganova N, Piecha G et al. Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am J Physiol Renal Physiol 2011; 300: F772-F782.
8. Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307.
9. Cardú s A, Panizo S, Parisi E et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-866.
10. Jono S, Nishizawa Y, Shioi A et al. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998; 98: 1302-1306.
11. Li X, Speer MY, Yang H et al. Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb Vasc Biol 2010; 30: 321-326.
12. Wu-Wong JR, Noonan W, Ma J et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther 2006; 318: 90-98.
13. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25- dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 2002; 139: 279-284.
14. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
15. Mathew S, Lund RJ, Chaudhary LR et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19: 1509-1519.
16. Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715.
17. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-897.
18. Jono S, McKee M, Murry C et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17.
19. Steitz S, Speer M, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154.
20. Reynolds J, Joannides A, Skepper J et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867.
21. Block G, Hulbert-Shearon T, Levin N et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
22. Kestenbaum B, Sampson J, Rudser K et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
23. Dhingra R, Sullivan L, Fox C et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885.
24. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
25. Towler DA. Calciotropic hormones and arterial physiology: 'D'-lightful insights. J Am Soc Nephrol 2007; 18: 369-373.
26. El-Abbadi MM, Pai AS, Leaf EM et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009; 75: 1297-1307.
27. Pai A, Leaf EM, El-Abbadi M et al. Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol 2011; 178: 764-773.
28. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
29. Li SA, Watanabe M, Yamada H et al. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 2004; 29: 91-99.
30. Morishita K, Shirai A, Kubota M et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 2001; 131: 3182-3188.
31. Ewald AJ, McBride H, Reddington M et al. Surface imaging microscopy, an automated method for visualizing whole embryo samples in three dimensions at high resolution. Dev Dyn 2002; 225: 369-375.
32. Lim K, Lu TS, Molostvov G et al. Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to FGF-23. Circulation 2012.
33. Chung AW, Yang HH, Kim JM et al. Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 2009; 120: 792-801.
34. Wasse H, Cardarelli F, De Staercke C et al. 25-hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients. BMC Nephrol 2011; 12: 24.
35. Price PA, Faus SA, Williamson MK. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 2000; 20: 317-327.
36. Slatopolsky E, Cozzolino M, Lu Y et al. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int 2003; 63: 2020-2027.
37. Finch JL, Tokumoto M, Nakamura H et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 2010; 298: F1315-F1322.
38. Koh N, Fujimori T, Nishiguchi S et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001; 280: 1015-1020.
39. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-136.
40. Hu MC, Shi M, Zhang J et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24: 3438-3450.
41. Larsson TE. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dial Transplant 2010; 25: 1376-1381.
42. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281: 6120-6123.
43. Goetz R, Nakada Y, Hu MC et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA 2010; 107: 407-412.
44. Lau WL, Pai A, Mae JM et al. Direct effects of phosphate on vascular cell function. Advances in Chronic Kidney Disease 2011; 18: 105-112.
45. Block G, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
46. Chertow G, Burke S, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
47. Wu-Wong JR, Nakane M, Ma J et al. Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells. Am J Physiol Renal Physiol 2007; 293: F1592-F1604.
48. Tsujikawa H, Kurotaki Y, Fujimori T et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003; 17: 2393-2403.
49. Forster RE, Jurutka PW, Hsieh JC et al. Vitamin D receptor controls expression of the anti-aging klotho gene in mouse and human renal cells. Biochem Biophys Res Commun 2011; 414: 557-562.
50. Haussler MR, Haussler CA, Whitfield GK et al. The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the 'Fountain of Youth' to mediate healthful aging. J Steroid Biochem Mol Biol 2010; 121: 88-97.
51. Chen CD, Podvin S, Gillespie E et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007; 104: 19796-19801.
52. Bloch L, Sineshchekova O, Reichenbach D et al. Klotho is a substrate for alpha-, beta- and gamma-secretase. FEBS Lett 2009; 583: 3221-3224.
53. Kolek OI, Hines ER, Jones MD et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renalgastrointestinal- skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005; 289: G1036-G1042.
54. Saito H, Maeda A, Ohtomo S et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280: 2543-2549.
55. Yu X, Sabbagh Y, Davis SI et al. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 2005; 36: 971-977.
56. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
57. Isakova T, Xie H, Barchi-Chung A et al. Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Clin J Am Soc Nephrol 2012; 7: 820-828.
58. Wada T, McKee M, Steitz S et al. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84: 166-178.
59. Schlieper G, Aretz A, Verberckmoes SC et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol 2010; 21: 689-696.
60. Zebger-Gong H, Mu? ller D, Diercke M et al. 1,25-Dihydroxyvitamin D3- induced aortic calcifications in experimental uremia: up-regulation of osteoblast markers, calcium-transporting proteins and osterix. J Hypertens 2011; 29: 339-348.
61. Starcher BC. Determination of the elastin content of tissues by measuring desmosine and isodesmosine. Anal Biochem 1977; 79: 11-15.